Previous close | 2.2300 |
Open | 2.2050 |
Bid | 2.0300 x 0 |
Ask | 2.1800 x 0 |
Day's range | 2.0798 - 2.2050 |
52-week range | 2.0798 - 3.0712 |
Volume | |
Avg. volume | 802 |
Market cap | 175.162M |
Beta (5Y monthly) | 0.60 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
MARSEILLE, France, June 04, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced favorable results from the Phase 2 TELLOMAK study with lacutamab in mycosis fungoides (MF). The results were presented at the ASCO 2024 Annual Meeting, in Chicago, Illinois.
MARSEILLE, France, May 28, 2024--Innate Pharma announces its participation in upcoming investor conferences
MARSEILLE, France, May 24, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today that five abstracts with Innate’s drug candidates have been accepted for the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place May 31-June 4, 2024 in Chicago, Illinois.